Rybelsus®

Semaglutide

Rybelsus tabletten (semaglutide) is een receptgeneesmiddel dat wordt gebruikt bij volwassenen met type 2 diabetes mellitus om de bloedsuikerspiegel te verlagen. Rybelsus kan worden voorgeschreven wanneer andere diabetesgeneesmiddelen zonder succes zijn geprobeerd en moet worden gebruikt in combinatie met dieet en lichaamsbeweging. Rybelsus tabletten werken om de bloedsuikerspiegel (glucose) te verlagen door de hoeveelheid insuline die vrijkomt te verhogen en de glucagon secretie te verminderen. Dit geneesmiddel kan ook vertragen maaglediging na het eten.
more
Pakket Per pil Prijs Besparingen Bestelling
90 tablet
Gratis AirMail verzending Hot
€ 14.30
€ 1287.45€ 14.30
€ 171.57
60 tablet
Gratis AirMail verzending Hot
€ 15.26
€ 915.50€ 15.26
€ 57.17
30 tablet
Gratis AirMail verzending Hot
€ 16.21
€ 486.34€ 16.21
Pakket Per pil Prijs Besparingen Bestelling
90 tablet
Gratis AirMail verzending Hot
€ 17.17
€ 1544.95€ 17.17
€ 85.74
60 tablet
Gratis AirMail verzending Hot
€ 17.64
€ 1058.56€ 17.64
€ 28.56
30 tablet
Gratis AirMail verzending Hot
€ 18.12
€ 543.56€ 18.12
Pakket Per pil Prijs Besparingen Bestelling
90 tablet
Gratis AirMail verzending Hot
€ 20.50
€ 1845.36€ 20.50
€ 85.74
60 tablet
Gratis AirMail verzending Hot
€ 20.98
€ 1258.84€ 20.98
€ 28.56
30 tablet
Gratis AirMail verzending Hot
€ 21.46
€ 643.70€ 21.46
Rybelsus

Merk(en)

Producent

  • Novo Nordisc India Pvt. Ltd

Ziektes

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.